ArticleBlood2023

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.

Robert J Kreitman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.